This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Paret, G. Articles by Barzilay, Z. Search for Related Content PubMed PubMed Citation Articles by Paret, G. Articles by Barzilay, Z. Social Bookmarking                         What's this?

Vipera palaestinae snake envenomations: experience in children

Pediatric ICU, The Chaim Sheba Medical Center

R. Ben-Abraham

Pediatric ICU, The Chaim Sheba Medical Center

D. Ezra

Pediatric Toxicology, The Chaim Sheba Medical Center, Tel Hashomer

D. Shrem

Pediatric ICU, The Chaim Sheba Medical Center

G. Eshel

Pediatric ICU, The Chaim Sheba Medical Center

A. Vardi

Pediatric ICU, The Chaim Sheba Medical Center

E. Winkler

Pediatric ICU, The Chaim Sheba Medical Center

Z. Barzilay

Pediatric ICU, The Chaim Sheba Medical Center

In Israel, Vipera palaestinae (V. palaestinae) is the most common venomous snake, accounting for 100 - 300 reported cases of envenomation every year. However, V. palaestinae snakebites in children have not been exten sively investigated. The demographic features, treatment and outcome of V. palaestinae envenomation in 37 children treated in two medical centers over a 9 year period were retrospectively reviewed. The victims age ranged from 2-18 years with a mean age of 8.9 years. Twenty-nine children were males and eight were females. Twenty-one patients resided in rural areas, and 16 children were living in urban areas. Twenty-three (63%) of the patients were bitten on the lower limb; Twelve (33%) on the upper limb, and two on the head or neck (4%). Using a grading scale of one to three from minimal to severe envenomation, 15 (40.5%), 15 (40.5%) and 7 (19%) patients had mild, moderate and severe envenomation, respec tively. Major complications of envenomation that were manifested after arrival consisted of compartment syn drome (two patients) and respiratory dysfunction (two patients).

Specific monovalent antiserum for the treatment of V. palaestinae bite was given to 16 children (43%) of whom, four patients were in the severe group, seven and five in the moderate and mild groups respectively. No patient suffered a significant infection, tissue loss, permanent disability or death. We conclude that early ICU admission along with close monitoring and antivenom therapy is important in reducing morbidity and mortality in children systemically envenomed by V. palaestinae.

Key Words: antivenom treatment • Vipera palaestinae • envenoma tion

Human & Experimental Toxicology, Vol. 16, No. 11, 683-687 (1997)
DOI: 10.1177/096032719701601110


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?